NMN/NR and Levothyroxine Interaction: Safety, Timing, and What the Evidence Says

Why This Question Matters for Thyroid Patients

Levothyroxine is the most prescribed medication in the United States, with over 100 million dispensed prescriptions annually [1]. NAD+ precursor supplements, particularly NMN and NR, have gained rapid consumer adoption based on preclinical longevity data and a growing number of human pharmacokinetic trials [2]. The overlap between these two populations is large: hypothyroid patients seeking anti-aging or metabolic optimization frequently ask whether their morning thyroid pill is compatible with an NAD+ booster.

The short answer is that no interaction has been reported. The longer answer requires understanding why levothyroxine is uniquely vulnerable to absorption interference, whether NMN or NR share any of the chemical properties that cause known interactions, and what monitoring makes sense when combining the two.

Levothyroxine's FDA-approved labeling lists over a dozen categories of substances that reduce its absorption, including calcium salts, ferrous sulfate, aluminum-containing antacids, proton pump inhibitors, bile acid sequestrants, sevelamer, and soy-based foods [3]. The common thread among these agents is either direct chemical binding (chelation) or alteration of gastric pH. NMN and NR do not fall into either category based on their known chemistry.

Pharmacokinetic Profile of Levothyroxine

Levothyroxine (T4) is absorbed primarily in the jejunum and upper ileum, with peak serum concentrations reached approximately 2 to 4 hours after oral ingestion [3]. Fasting bioavailability is roughly 80%, but this drops to 64% or lower when the drug is taken with food or interacting substances [4]. The narrow therapeutic index means that even a 20% shift in absorbed dose can push TSH outside the target range.

The drug is not a substrate of cytochrome P450 enzymes for its primary metabolic conversion. T4 is deiodinated to T3 (the active hormone) by type 1 and type 2 deiodinases, and it undergoes glucuronidation and sulfation in the liver [3]. P-glycoprotein does not play a clinically meaningful role in levothyroxine disposition.

This pharmacokinetic profile means the interaction risk with any co-administered substance is almost entirely an absorption-phase concern. Once levothyroxine reaches the bloodstream, the likelihood of a drug-drug interaction at the metabolic level is low.

"Levothyroxine absorption is exquisitely sensitive to gastric pH and to physical binding by co-ingested substances," notes the American Thyroid Association's 2014 guidelines for hypothyroidism management. "Patients should take levothyroxine on an empty stomach, 30 to 60 minutes before breakfast" [5].

Pharmacokinetic Profile of NMN and NR

NMN (nicotinamide mononucleotide) is a nucleotide composed of nicotinamide, a ribose sugar, and a phosphate group. After oral ingestion, NMN is rapidly converted to NAD+ through the salvage pathway, primarily via nicotinamide phosphoribosyltransferase (NAMPT) [6]. A 2022 randomized, double-blind trial (N=80) by Yi et al. demonstrated that 1,000 mg of oral NMN daily for 60 days increased blood NAD+ levels by 38% compared to placebo, with no serious adverse events reported [7].

NR (nicotinamide riboside) follows a slightly different metabolic route, entering cells via equilibrative nucleoside transporters and being phosphorylated to NMN by nicotinamide riboside kinases (NRK1 and NRK2) before conversion to NAD+ [8]. The CHROMAVITA trial showed that 1,000 mg daily NR for 6 weeks raised whole-blood NAD+ by 51% in healthy adults (N=40) [9].

Neither NMN nor NR is a known substrate, inhibitor, or inducer of any cytochrome P450 isoenzyme. Neither compound has demonstrated P-glycoprotein modulation in published in vitro or clinical studies [6][8]. Their metabolism occurs entirely within the NAD+ salvage pathway, which is enzymatically distinct from the phase I and phase II systems responsible for most drug-drug interactions.

Theoretical Interaction Mechanisms: What Could Go Wrong

Three theoretical mechanisms deserve evaluation, even though none has been confirmed clinically.

Absorption competition. Levothyroxine absorption depends on an acidic gastric environment and an empty stomach. NMN capsules typically contain 250 to 500 mg of active compound plus excipients (cellulose, magnesium stearate, silicon dioxide). This physical mass in the stomach could theoretically delay gastric emptying or alter the local pH microenvironment. A 2017 study by Skelin et al. cataloged factors affecting levothyroxine absorption and found that even coffee (no caloric content) reduced T4 absorption by approximately 36% when consumed simultaneously [10]. The mechanism was attributed to altered gastric motility rather than chemical binding. Any capsule or tablet taken alongside levothyroxine could pose a similar risk.

Nicotinamide-mediated effects on thyroid function. High-dose niacin (nicotinic acid, a related B3 vitamer) has been associated with decreased TSH in isolated case reports, though the mechanism remains unclear [11]. NMN and NR are metabolically distinct from nicotinic acid: they do not activate the GPR109A receptor responsible for niacin's flushing and lipid effects, and they generate NAD+ through a different enzymatic route. No study has linked NMN or NR supplementation to altered TSH, free T4, or free T3 levels.

Sirtuin activation and thyroid hormone metabolism. NAD+ is a required co-substrate for sirtuin enzymes (SIRT1 through SIRT7). SIRT1 has been shown to modulate thyroid hormone receptor activity in cell culture models [12]. Whether raising NAD+ levels by 30 to 50% through oral supplementation produces a clinically detectable change in thyroid hormone signaling in humans is unknown. No trial has measured thyroid function as an endpoint in NMN or NR studies.

What the FDA Labels and Databases Show

The FDA label for levothyroxine sodium (Synthroid, AbbVie) lists specific drug interactions organized by mechanism: drugs that alter absorption, drugs that alter serum transport protein concentrations, drugs that affect T4 metabolism, and drugs with actions altered by thyroid status [3]. NMN and NR appear in none of these categories.

The FDA Adverse Event Reporting System (FAERS) contains no reports linking NMN or NR supplementation to levothyroxine treatment failure, elevated TSH, or thyrotoxicosis as of the most recent quarterly data release [13]. This absence is not proof of safety (supplements are underreported in FAERS), but it does indicate that no signal has emerged despite widespread concurrent use.

NR holds Generally Recognized as Safe (GRAS) status from the FDA at doses up to 300 mg per day (FDA GRN No. 635), and NMN received a similar GRAS determination (GRN No. 1062) at doses up to 600 mg daily [14]. Neither GRAS review identified drug interactions as a concern.

Practical Dosing Protocol: How to Combine Safely

The absence of a documented interaction does not eliminate the need for structured dosing. Levothyroxine's sensitivity to co-ingested substances makes timing discipline the single most protective measure.

Step 1: Protect the levothyroxine absorption window. Take levothyroxine first thing in the morning on a completely empty stomach with a full glass of water. Wait at least 60 minutes before taking NMN, NR, or any other supplement. The American Thyroid Association recommends a 60-minute fast for optimal absorption [5]. Some endocrinologists suggest bedtime dosing of levothyroxine (at least 3 hours after the last meal) as an alternative; a 2010 crossover trial (N=90) by Bolk et al. found that bedtime administration actually improved TSH and free T4 levels compared to morning dosing [15].

Step 2: Choose a consistent NMN/NR schedule. If taking levothyroxine in the morning, NMN or NR can be taken with breakfast or at midday. Consistency matters more than the specific hour, because any change in timing pattern could shift levothyroxine absorption characteristics and confound TSH interpretation.

Step 3: Monitor TSH at 6 to 8 weeks. The Endocrine Society recommends rechecking TSH 6 to 8 weeks after any change in levothyroxine dose, formulation, or co-administered substance [16]. Adding or discontinuing an NAD+ precursor qualifies. If TSH remains within the patient's target range (typically 0.5 to 2.5 mIU/L for most adults), no dose adjustment is needed.

Step 4: Track symptoms, not just labs. Fatigue, cold intolerance, weight gain, or palpitations appearing after starting NMN or NR should prompt TSH testing even if the 6-week check is not yet due. These symptoms overlap with both hypothyroidism and the adjustment phase some users report when starting NAD+ precursors.

Special Populations: Thyroid Cancer, Pregnancy, and the Elderly

Post-thyroidectomy patients on TSH-suppressive dosing. These patients typically target a TSH below 0.1 mIU/L to reduce recurrence risk. Any absorption interference that raises TSH even modestly could have oncologic implications. For this group, a 90-minute separation between levothyroxine and NMN/NR is prudent, and TSH should be checked at 4 weeks rather than 6 to 8 [16].

Pregnant patients. Levothyroxine requirements increase by 25 to 50% during pregnancy, and undertreated maternal hypothyroidism carries risks of impaired fetal neurodevelopment [17]. NMN and NR have not been studied in pregnant humans. The lack of safety data in this population, combined with the high stakes of thyroid undertreatment, means NMN and NR should generally be discontinued during pregnancy unless a treating physician explicitly endorses continued use.

Elderly patients (age 65 and older). Gastric acid secretion declines with age, which already reduces levothyroxine absorption. Adding any oral supplement increases the theoretical risk of further absorption reduction. The 60-minute separation rule is the minimum for this group; some geriatric endocrinologists recommend 2 hours [5].

"For elderly patients on multiple medications, we often recommend a blanket 2-hour separation between levothyroxine and all other oral agents," notes the American Association of Clinical Endocrinology's 2023 thyroid guidelines update [18].

NMN vs. NR: Does the Choice Affect Interaction Risk?

From an interaction standpoint with levothyroxine, NMN and NR are functionally equivalent risks. Both are water-soluble, both are absorbed in the small intestine, and neither binds divalent cations or alters gastric pH in a pharmacologically meaningful way.

The choice between NMN and NR should be based on the available efficacy and safety data for each compound, not on differential interaction risk with thyroid medication. NR has a longer track record in published human trials, including the Elysium/ChromaDex studies, while NMN has a rapidly expanding evidence base from trials conducted primarily in Japan and China [7][9].

One practical difference: NR is available in both capsule and sublingual forms. Sublingual NR bypasses gastric absorption entirely, which would eliminate even the theoretical absorption competition with levothyroxine. No study has tested whether sublingual NR administration changes NAD+ bioavailability compared to oral capsules, so this remains a hypothesis rather than a recommendation.

Monitoring Checklist for Clinicians

A structured monitoring approach for patients combining NAD+ precursors with levothyroxine includes four elements. First, obtain a baseline TSH and free T4 before the patient starts NMN or NR. Second, recheck TSH at 6 to 8 weeks. Third, if TSH has shifted by more than 0.5 mIU/L in either direction without a levothyroxine dose change, evaluate timing adherence before adjusting the levothyroxine dose. Fourth, repeat TSH annually if the combination remains stable.

Document the supplement name, dose, and manufacturer in the medication list. NMN and NR products vary widely in actual content versus label claims; a 2022 analysis by ConsumerLab found that 4 of 21 tested NMN products contained less than 80% of labeled NMN content [19]. Switching brands could effectively change the "dose" and alter any absorption dynamics.

Patients taking levothyroxine 25 mcg or 50 mcg tablets (common starting doses for subclinical hypothyroidism or elderly patients) are more sensitive to proportional absorption changes than those on higher doses. A 20% absorption drop on a 50 mcg dose loses 10 mcg of T4, which may be enough to shift TSH outside the reference range. The same proportional drop on 150 mcg loses 30 mcg but may remain within the compensatory range of the hypothalamic-pituitary-thyroid axis.